Amneal Pharmaceuticals, Inc.

AMRX

US03168L1052

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
6.67 ^USD	-1.19%		+5.04%	+9.88%

07-01	Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments	MT
07-01	Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar	CI

Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell Small Cap Comp Growth Index

July 30, 2024

Latest news about Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments	07-01	MT
Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar	07-01	CI
Kashiv Biosciences Enters into Exclusive Licensing Agreement with Amneal Pharmaceuticals, Inc. for Commercialization of A Proposed Biosimilar to XOLAIR®	07-01	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 3000 Growth Index	06-30	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 3000E Growth Index	06-30	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth Index	06-30	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2500 Growth Index	06-30	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell Small Cap Comp Growth Index	06-30	CI
Transcript : Amneal Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 01:30 PM	06-05
Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies	06-05	CI
Amneal Pharmaceuticals Begins Supplying Generic Version of Narcan	05-22	DJ
Amneal Begins Supplying Over-The-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California	05-22	CI
Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating	05-06	MT
Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating	05-03	MT
Drugmaker Amneal agrees to $270 million U.S. opioid settlement	05-03	RE
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	05-03	MT
Transcript : Amneal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 03, 2024	05-03
Amneal Pharmaceuticals Q1 Adjusted Earnings, Revenue Climb	05-03	MT
(AMRX) AMNEAL PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $0.53 - $0.63	05-03	MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Reports Q1 Revenue $659.2M, vs. Street Est of $619M	05-03	MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Posts Q1 EPS $0.14, vs. Street Est of $0.09	05-03	MT
North American Morning Briefing : Apple, Amgen -2-	05-03	DJ
Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for Full Year 2024	05-03	CI
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-03	CI
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	04-24	MT

Chart Amneal Pharmaceuticals, Inc.

Duration

Period

More charts

Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Companyâs Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segmentâs portfolio includes central nervous system disorders (Parkinsonâs disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Companyâs AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.

Sector

Pharmaceuticals

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Amneal Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.67 USD

Average target price

8.25 USD

Spread / Average Target

+23.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AMNEAL PHARMACEUTICALS, INC.	+9.88%	2.06B
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B
PFIZER, INC.	-2.57%	159B

Other Pharmaceuticals